Dr. Kostyk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2050 Kenny Rd
Columbus, OH 43221Phone+1 614-293-4969Fax+1 614-293-6111
Summary
- Dr. Sandra Kostyk is a neurologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. She received her PhD in Pharmacological and Physiological Sciences from the University of Chicago and her medical degree from University of Chicago Pritzker School of Medicine. She completed her neurology residency at the Massachusetts General Hospital and her K11 Physician Scientist Award on neurotrophic growth factors at Harvard. She specializes in Huntington's disease and other neurodegenerative disorders including Parkinson's disease, Lewy Body Disease and dementias. She is the Co-Chair of the Executive Membership Committee of the Huntington Study Group and a member of the Parkinson Study Group. She has participated in numerous clinical research trials. She is the medical director of the HDSA Center of Excellence at The Ohio State University Wexner Medical Center, a multidisciplinary clinic focused on Huntingtons disease.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1986 - 1989
- University of ChicagoInternship, Internal Medicine, 1985 - 1986
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
Certifications & Licensure
- OH State Medical License 1998 - 2026
- MA State Medical License 1989 - 2002
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Exceptional Women in Medicine (Neurology) Castle Connolly, 2020
- Physician Scientist K11 NIH/NEI, 1989-1994
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
- Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease Start of enrollment: 2010 Apr 01
- Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 408 citationsAAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialPeter A. LeWitt, Ali R. Rezai, Maureen A. Leehey, Steven G. Ojemann, Alice W. Flaherty
The Lancet. Neurology. 2011-04-01 - 11 citationsImpact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.Deb A. Kegelmeyer, Anne D. Kloos, Nora E. Fritz, Marianne M. Fiumedora, Susan White
Journal of the Neurological Sciences. 2014-12-15 - 90 citationsLong-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek
Movement Disorders. 2009-03-15
Press Mentions
- CIRM Funded Trial for Parkinson’s Treats First PatientSeptember 14th, 2020
- Wexner Medical Center Performs First Gene Therapy Brain Infusion for Parkinson’s DiseaseSeptember 4th, 2020
- The First Gene Therapy Clinical Trial in Huntington’s Disease Initiated by uniQureNovember 3rd, 2019
- Join now to see all
Grant Support
- FGF In The Visual SystemNational Eye Institute1991–1993
- FGF In The Visual SystemNational Eye Institute1989–1990
Professional Memberships
- Member
- Member
- Huntington Study GroupMember
- Parkinson Study GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: